Endo to pay $192.7M in Lidoderm off-label marketing

Malvern-based Endo Health Solutions Inc. and its subsidiary Endo Pharmaceuticals Inc. have agreed to pay $192.7 million to resolve allegations of off-label marketing of the prescription pain patch Lidoderm for uses not approved by the Food and Drug Administration, the U.S. Justice Department said Friday.



http://ift.tt/1f7hXAB